{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:49:07Z","timestamp":1787662147741,"version":"build-2736575974"},"reference-count":72,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1957,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1111\/j.1365-2265.2010.03814.x","type":"journal-article","created":{"date-parts":[[2010,4,23]],"date-time":"2010-04-23T09:15:27Z","timestamp":1272014127000},"page":"141-147","source":"Crossref","is-referenced-by-count":79,"title":["Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management"],"prefix":"10.1111","volume":"74","author":[{"given":"Richard I. G.","family":"Holt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Peveler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,4,23]]},"reference":[{"issue":"2 Suppl","key":"10.1111\/j.1365-2265.2010.03814.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0269216307087147","article-title":"The evolution of hyperprolactinaemia as an entity in psychiatric patients","volume":"22","author":"Kohen","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"2 Suppl","key":"10.1111\/j.1365-2265.2010.03814.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","article-title":"Antipsychotics and hyperprolactinaemia: clinical recommendations","volume":"22","author":"Peveler","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"2 Suppl","key":"10.1111\/j.1365-2265.2010.03814.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0269881107088435","article-title":"A review of the association between antipsychotic use and hyperprolactinaemia","volume":"22","author":"Bushe","year":"2008","journal-title":"Journal of Psychopharmacology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/JCP.0b013e31818ba5d8","article-title":"Antipsychotic-induced hyperprolactinemia: a cross-sectional survey","volume":"28","author":"Johnsen","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","article-title":"Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics","volume":"21","author":"Bushe","year":"2007","journal-title":"Journal of Psychopharmacology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pnpbp.2006.10.007","article-title":"The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study","volume":"31","author":"Jakovljevic","year":"2007","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"Suppl 2","key":"10.1111\/j.1365-2265.2010.03814.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","article-title":"Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00002018-200932040-00006","article-title":"Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings","volume":"32","author":"Rani","year":"2009","journal-title":"Drug Safety"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB9|cit9","first-page":"419","article-title":"Hyperprolactinemia after low dose of amisulpride","volume":"25","author":"Kopecek","year":"2004","journal-title":"Neuro Endocrinology Letters"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v66n0614","article-title":"Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients","volume":"66","author":"Melkersson","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB11|cit11","first-page":"803","article-title":"Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia","volume":"27","author":"Kopecek","year":"2006","journal-title":"Neuro Endocrinology Letters"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","article-title":"Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial","volume":"162","author":"Schooler","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.schres.2006.11.004","article-title":"Prolactin, menstrual irregularities, quality of life","volume":"91","author":"Wong","year":"2007","journal-title":"Schizophrenia Research"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2 Suppl","key":"10.1111\/j.1365-2265.2010.03814.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881107088436","article-title":"Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics","volume":"22","author":"Bushe","year":"2008","journal-title":"Journal of Psychopharmacology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","article-title":"Elevation of prolactin levels by atypical antipsychotics","volume":"159","author":"Turrone","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 13","key":"10.1111\/j.1365-2265.2010.03814.x-BIB18|cit18","first-page":"5","article-title":"Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing","volume":"63","author":"Nemeroff","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clinical Therapeutics"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0165-1781(81)90078-0","article-title":"Tolerance to the prolactin-elevating effect of neuroleptics","volume":"5","author":"Brown","year":"1981","journal-title":"Psychiatry Research"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1600-0447.2006.00897.x","article-title":"Prolactin level during 5\u2003years of risperidone treatment in patients with psychotic disorders","volume":"115","author":"Eberhard","year":"2007","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"2 Suppl","key":"10.1111\/j.1365-2265.2010.03814.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","article-title":"Prolactin and dopamine: what is the connection? A review article","volume":"22","author":"Fitzgerald","year":"2008","journal-title":"Journal of Psychopharmacology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2265.1981.tb00666.x","article-title":"Endocrine effects of domperidone: a peripheral dopamine blocking agent","volume":"15","author":"Brown","year":"1981","journal-title":"Clinical Endocrinology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hup.811","article-title":"Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite","volume":"21","author":"Melkersson","year":"2006","journal-title":"Human Psychopharmacology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels","volume":"162","author":"Knegtering","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","article-title":"Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"Pharmacogenetics and Genomics"},{"issue":"2 Suppl","key":"10.1111\/j.1365-2265.2010.03814.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0269881107088438","article-title":"The impact of hyperprolactinaemia on sexual function in patients with psychosis","volume":"22","author":"Smith","year":"2008","journal-title":"Journal of Psychopharmacology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0010-440X(96)90052-8","article-title":"Sexual disorders in nonacute psychiatric outpatients","volume":"37","author":"Kockott","year":"1996","journal-title":"Comprehensive Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/00926230600666378","article-title":"A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning","volume":"32","author":"Knegtering","year":"2006","journal-title":"Journal of Sex and Marital Therapy"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.eurpsy.2005.12.005","article-title":"Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study","volume":"21","author":"Dossenbach","year":"2006","journal-title":"European Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/713847170","article-title":"Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study","volume":"29","author":"Bobes","year":"2003","journal-title":"Journal of Sex and Marital Therapy"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.jcp.0000115664.45074.44","article-title":"Prolactin levels and erectile function in patients treated with risperidone","volume":"24","author":"Spollen","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJM198012253032605","article-title":"Decreased bone density in hyperprolactinemic women","volume":"303","author":"Klibanski","year":"1980","journal-title":"The New England Journal of Medicine"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1210\/jcem-59-6-1050","article-title":"Vertebral body bone mineral content in hyperprolactinemic women","volume":"59","author":"Koppelman","year":"1984","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-110-7-526","article-title":"Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism","volume":"110","author":"Greenspan","year":"1989","journal-title":"Annals of Internal Medicine"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2265.2000.00902.x","article-title":"Prolactinomas in adolescents: persistent bone loss after 2\u2003years of prolactin normalization","volume":"52","author":"Colao","year":"2000","journal-title":"Clinical Endocrinology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB40|cit40","first-page":"996","article-title":"Osteopenia in women with hypothalamic amenorrhea: a prospective study","volume":"78","author":"Biller","year":"1991","journal-title":"Obstetrics and Gynecology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"E1216","DOI":"10.1152\/ajpendo.2000.279.6.E1216","article-title":"Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat","volume":"279","author":"Coss","year":"2000","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1043-2760(00)00351-9","article-title":"Receptor activator of nuclear factor kappa B ligand (RANKL): another link between breast and bone","volume":"12","author":"Martin","year":"2001","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1192\/bjp.bp.106.023671","article-title":"Risk of hip fracture in patients with a history of schizophrenia","volume":"190","author":"Howard","year":"2007","journal-title":"British Journal of Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.4088\/JCP.v69n0907","article-title":"Sex- and age-specific incidence of fractures in mental illness: a historical, population-based cohort study","volume":"69","author":"Abel","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00198-005-0065-y","article-title":"Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture","volume":"17","author":"Vestergaard","year":"2006","journal-title":"Osteoporosis International"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00198-008-0826-5","article-title":"Antipsychotic use and the risk of hip\/femur fracture: a population-based case-control study","volume":"20","author":"Pouwels","year":"2009","journal-title":"Osteoporosis International"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v64n0704","article-title":"Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients","volume":"64","author":"Becker","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","article-title":"Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?","volume":"25","author":"O\u2019Keane","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1592\/phco.26.6.748","article-title":"Atypical antipsychotics and pituitary tumors: a pharmacovigilance study","volume":"26","author":"Szarfman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/PL00007539","article-title":"Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder","volume":"250","author":"Melkersson","year":"2000","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1744-859X-8-5","article-title":"Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study","volume":"8","author":"Gianfrancesco","year":"2009","journal-title":"Annals of General Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1600-0447.1988.tb05106.x","article-title":"The effect of neuroleptics on prolactinoma growth in a Jordanian schizophrenic girl","volume":"77","author":"Daradkeh","year":"1988","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/00006842-200009000-00018","article-title":"Effect of risperidone on prolactinoma growth in a psychotic woman","volume":"62","author":"Pal","year":"2000","journal-title":"Psychosomatic Medicine"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2004-815474","article-title":"Effect of risperidone on prolactinoma--a case report","volume":"37","author":"Mendhekar","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1210\/en.140.11.5348","article-title":"Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice","volume":"140","author":"Asa","year":"1999","journal-title":"Endocrinology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beem.2005.09.008","article-title":"Regulation of endocrine-disrupting chemicals: critical overview and deficiencies in toxicology and risk assessment for human health","volume":"20","author":"Harvey","year":"2006","journal-title":"Best Practice and Research. Clinical Endocrinology and Metabolism"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0447.2008.01163.x","article-title":"Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis","volume":"117","author":"Catts","year":"2008","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine antagonists and the development of breast cancer","volume":"59","author":"Wang","year":"2002","journal-title":"Archives of General Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.bjc.6603259","article-title":"Cancer risk among users of neuroleptic medication: a population-based cohort study","volume":"95","author":"Dalton","year":"2006","journal-title":"British Journal of Cancer"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB60|cit60","doi-asserted-by":"crossref","DOI":"10.1201\/b21605","volume-title":"The Maudsley Prescribing Guidelines","author":"Taylor","year":"2007"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-1614.2005.01516.x","article-title":"Clinical practice guidelines for the treatment of schizophrenia and related disorders","volume":"39","author":"Royal Australian and New Zealand College of Psychiatrists","year":"2005","journal-title":"The Australian and New Zealand Journal of Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/15622970510030090","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia","volume":"6","author":"Falkai","year":"2005","journal-title":"The World Journal of Biological Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB63|cit63","unstructured":"National Institute for Clinical Excellence (NICE) 2009 Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care (update) CG82 http:\/\/www.nice.org.uk"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB64|cit64","unstructured":"National Institute for Clinical Excellence (NICE) The management of bipolar disorder in adults, children and adolescents, in primary and secondary care CG38 http:\/\/www.nice.org.uk"},{"issue":"2 Suppl","key":"10.1111\/j.1365-2265.2010.03814.x-BIB65|cit65","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00198-003-1454-8","article-title":"A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis","volume":"14","author":"Hernandez","year":"2003","journal-title":"Osteoporosis International"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clinical Endocrinology"},{"issue":"2 Suppl","key":"10.1111\/j.1365-2265.2010.03814.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/0269881107087373","article-title":"Current guidelines and their recommendations for prolactin monitoring in psychosis","volume":"22","author":"Citrome","year":"2008","journal-title":"Journal of Psychopharmacology"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","article-title":"A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy","volume":"70","author":"Kane","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1590\/S1516-31802006000500012","article-title":"A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia","volume":"124","author":"Costa","year":"2006","journal-title":"S\u00e3o Paulo Medical Journal"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.genhosppsych.2007.11.002","article-title":"Cabergoline-induced psychotic exacerbation in schizophrenic patients","volume":"30","author":"Chang","year":"2008","journal-title":"General Hospital Psychiatry"},{"key":"10.1111\/j.1365-2265.2010.03814.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-244X-6-49","article-title":"Mammography stages of change in middle-aged women with schizophrenia: an exploratory analysis","volume":"6","author":"Lindamer","year":"2006","journal-title":"BMC Psychiatry"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2010.03814.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2265.2010.03814.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:50:22Z","timestamp":1711414222000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2010.03814.x"}},"subtitle":["Antipsychotics and hyperprolactinaemia"],"short-title":[],"issued":{"date-parts":[[2010,4,23]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03814.x","relation":{},"ISSN":["0300-0664"],"issn-type":[{"value":"0300-0664","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4,23]]}}}